An updated review of experimental rodent models of pulmonary hypertension and left heart disease
Left heart disease (LHD) is the leading cause of pulmonary hypertension (PH). Its recent growth has not been matched by the design of therapeutic agents directly targeting the disease. Effective therapies approved for pulmonary arterial hypertension (PAH) have been shown to be inefficient in patient...
Saved in:
Main Author: | Magdalena Jasińska-Stroschein (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2024-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Searching for Effective Treatments in HFpEF: Implications for Modeling the Disease in Rodents
by: Magdalena Jasińska-Stroschein
Published: (2023) -
Predictor factors of pulmonary hypertension in children with left-to-right shunting in acyanotic congenital heart disease
by: Weny Inrianto, et al.
Published: (2021) -
Experimental Pharmacology in Transgenic Rodent Models of Alzheimer's Disease
by: A. Claudio Cuello, et al.
Published: (2019) -
Safety and Efficacy of Sildenafil for Group 2 Pulmonary Hypertension in Left Heart Failure
by: Kinjal Desai, et al.
Published: (2023) -
Resveratrol in Rodent Models of Parkinson's Disease: A Systematic Review of Experimental Studies
by: Cheng-Fu Su, et al.
Published: (2021)